Company / EPS (Diluted)
Lipocine Inc. EPS (Diluted) History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.69
FY2025
5-year range
-$3.14 / -$0.01
FY2021-FY2025
Trend
+46.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-1.69.
Based on SEC 10-K filings.
-1.69 in FY2025.
Improved from $-2.15 to $-1.69 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 46.2% year-over-year.
- Peak eps (diluted) was recorded in FY2013.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.69 | +46.2% |
| FY2024 | -$3.14 | -46.0% |
| FY2023 | -$2.15 | -21400.0% |
| FY2022 | -$0.01 | +97.4% |
| FY2021 | -$0.38 | +24.0% |
| FY2020 | -$0.50 | +9.1% |
| FY2019 | -$0.55 | +47.1% |
| FY2018 | -$1.04 | -222.4% |
| FY2013 | $0.85 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026